부산대학교 도서관

Background and Design: Although some inflammatory markers were elevated in patients with psoriatic arthritis (PsA) compared to healthy controls, are few studies evaluated the effects of systemic treatments for PsA on these markers. The aim of this study is to investigate the changes in hemogram parameters and C-reactive protein (CRP) in PsA patients receiving systemic therapies. Materials and Methods: In this retrospective study, hemogram parameters, CRP, and systemic inflammation indices [neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)] of 50 PsA patients were analyzed before and in the third month of the treatments. Results: While mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and hemoglobin (Hb) were higher in the third month of all treatments compared to the baseline (p=0.009, 0.003, and 0.036, respectively), platelet, CRP and SII were lower (p=0.001, 0.000, and 0.000, respectively). In the biological therapy group (n=21), platelet, SIRI, and SII were lower, while MCHC was higher in the third month than baseline (p=0.023, 0.033, 0.000, and 0.003, respectively). CRP and SII were lower in the third month of the non-biologic treatment group (n=29) compared to the baseline, and MCH and mean corpuscular volume (MCV) were higher (p=0.001, 0.000, 0.027, and 0.044, respectively). No statistically different changes were recorded in NLR, PLR, and other parameters. Conclusion: Hb, MCH, and MCHC increased, and platelet, CRP, and SII decreased in the third month of all systemic therapies. MCV was higher in the non-biologic treatment group, and SIRI was lower in the biological treatment group in the third month than baseline. Therefore, these parameters may be useful for monitoring the effects of treatments in PsA.